WHWK Whitehawk Therapeutics, Inc.

NASDAQ
$3.74

Whitehawk Therapeutics, Inc. (WHWK) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.6% since its last earnings release on August 6, 2026.

Whitehawk Therapeutics Beat Consensus Estimates
Thursday, August 6, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.27)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.45

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Whitehawk Therapeutics, Inc.

Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.